Kessler Topaz Meltzer & Check, LLP Urges ADMA Investors Facing Losses to Reach Out
Kessler Topaz Meltzer & Check, LLP Calls on ADMA Investors to Take Action
In a recent announcement, Kessler Topaz Meltzer & Check, LLP, a prominent law firm specializing in securities litigation, is encouraging investors of ADMA Biologics, Inc. (NASDAQ: ADMA) who experienced financial losses from August 9, 2024, to March 25, 2026, to get in touch with the firm.
During this period, a class-action lawsuit was initiated citing securities fraud against ADMA Biologics. This legal action is being filed in the United States District Court for the District of New Jersey, with the specific case named Mazzarino v. ADMA Biologics, Inc., case number 226-cv-06918. The firm is actively seeking investors who wish to pursue potential recovery for their losses, with a deadline to file for lead plaintiff status set for August 10, 2026.
Background of the Class Period
The class period in question covers a vital timeframe for ADMA, where allegations include significant misstatements regarding the company's financial health and internal practices. The lawsuit highlights that investors were misled by the company's positive claims regarding operations and revenue growth.
Key allegations in the case state that ADMA Biologics engaged in undisclosed related party transactions and employed deceptive practices known as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.